A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults
with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia.
The anticipated time on study treatment is 16 weeks, and the target sample size is
approximately 208 individuals.